A Single-center, Single Blind Molecular and Functional Imaging Study to Assess GABAAalpha5 Receptor Expression, Occupancy and Functional Connectivity in the Brains of Individuals With Down Syndrome and Healthy Controls Following a Single Oral Administration of RG1662 or Placebo
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Basmisanil (Primary)
- Indications Cognition disorders; Down syndrome
- Focus Pharmacodynamics
- Sponsors Roche
- 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jun 2013 New trial record